18699-02-0

Basic information

• Product Name: Actarit
• Synonyms: (p-acetamidophenyl)-aceticaci;(p-acetamidophenyl)aceticacid;4-(acetylamino)-benzeneaceticaci;4-n-acetylaminophenylaceticacid;ms932;RARECHEM AL BO 1520;4-(acetylamino)-benzeneacetic acid;[4-(ACETYLAMINO)PHENYL]ACETIC ACID
• CAS NO: 18699-02-0
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• EINECS: 242-511-3
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 18699-02-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 173-175°C
• Boiling Point: 449.1 °C at 760 mmHg
• Flash Point: 225.4 °C
• Appearance: crystalline solid
• Density: 1.288 g/cm³
• Vapor Pressure: 7.52E-09mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: -20°C
• Solubility: DMSO, Ethanol, Methanol
• PKA: 4.34±0.10(Predicted)
• Merck: 14,133
• CAS DataBase Reference: Actarit(CAS DataBase Reference)
• NIST Chemistry Reference: Actarit(18699-02-0)
• EPA Substance Registry System: Actarit(18699-02-0)

Safety Data

• Safety Statements: 24/25
• RTECS: CY1542000
• Hazardous Substances Data: 18699-02-0(Hazardous Substances Data)

Usage

Description

Actarit is an orally administered disease-modifying antirheumatic drug launched in Japan. Although its structure resembles that of non-steroidal anti-inflammatory drugs, it has no effect on experimental acute inflammation and has no analgesic or antipyretic effects. Its preventative and therapeutic effects on adjuvant arthritis are mediated via modulation of production and serum level of interleukin-2 which enhances production of suppressor T-cells to the immune system, thereby, preventing development of articular lesions.

Chemical Properties

Crystalline Solid

Originator

Nippon Shlnyaku;Mltaublshl Kasel (Japan)

Uses

Different sources of media describe the Uses of 18699-02-0 differently. You can refer to the following data:
1. Antiarthritic
2. Chronic rheumatoid arthritis

Brand name

Orcl; Mover

Purification Methods

Crystallise the acid from MeOH/Me2CO, aqueous EtOH or H2O. The amide has m 231o (from 50% aqueous EtOH). [Gabriel Chem Ber 15 841 1882, Cerecedo et al. J Biol Chem 42 238 1924, Tramontano et al. J Am Chem Soc 110 2282 1988, Beilstein 14 II 281.]

InChI:InChI=1/C10H11NO3/c1-7(12)11-9-4-2-8(3-5-9)6-10(13)14/h2-5H,6H2,1H3,(H,11,12)(H,13,14)

Upstream product

• 1197-55-3 4-aminophenylacetic acid 
• 108-24-7 acetic anhydride 
• 64-19-7 acetic acid 
• 75-36-5 acetyl chloride 
• 127-19-5 N,N-dimethyl acetamide 
• 106664-49-7 4'-acetamidophenyl 4-acetamidophenylacetate 
• 335200-33-4 {4-[2-(4-{2-[4-(2-{4-[2-(4-Acetylamino-phenyl)-acetoxy]-phenyl}-acetoxy)-phenyl]-acetoxy}-phenyl)-acetoxy]-phenyl}-acetic acid 
• 335200-29-8 [4-(2-{4-[2-(4-Acetylamino-phenyl)-acetoxy]-phenyl}-acetoxy)-phenyl]-acetic acid 
• 113180-61-3 4'-(4''-carboxybutyramido)phenyl 4-acetamidophenylacetate 
• 97562-37-3 4-(2-nitrovinyl)benzenamine 
• 556-18-3 4-aminobenzaldehyde 

Downstream Products

• 23784-25-0 N-(4'-hydroxy-trans-stilben-4-yl)-acetamide 
• 118380-00-0 (4-Acetylamino-phenyl)-acetic acid 2-methyl-quinolin-8-yl ester 
• 118380-05-5 2-(4-Acetylamino-phenyl)-N-(2-methyl-quinolin-8-yl)-acetamide 
• 142613-57-8 (4-Acetylamino-phenyl)-acetic acid vinyl ester 
• 114886-38-3 (4-Acetylamino-phenyl)-acetic acid phenyl ester 
• 2952-00-3 trans-2-(4-aminocyclohexyl)acetic acid 
• 16375-88-5 N-(4-hydroxymethylphenyl)acetamide 
• 122-85-0 para-acetamidobenzaldehyde 
• 103-84-4 Acetanilid 
• 637335-58-1 2-(4-acetylamino-phenyl)-N-(6-amino-1-butyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-acetamide 
• 101349-30-8 methyl 4-amino-3-chlorobenzene-1-acetate 
• 59235-32-4 (3-chloro-4-acetamino-phenyl)-acetic acid 
• 31733-58-1 N-benzyl-2-(4-aminophenyl)acetamide 

Related news

Short communicationSuppressive effect of Actarit (cas 18699-02-0) on IgA production in mice: Activation of Cd4+ suppressor T-cells in Peyer's patches09/27/2019

We examined the effects of actarit, a new antirheumatic drug, on antibody production after LPS stimulation in mice. Actarit did not affect the proliferative response of B-cells stimulated with LPS or anti-mouse μ-chain antibody plus rIL-4. Lymphocytes in the Peyer's patches (PP) of mice wi...detailed

Relevant articles and documents

HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME

The present invention relates to a hyaluronic acid derivative in which an anti-inflammatory drug is bound via a covalent bond, wherein the structure of the hyaluronic acid derivative is represented by following formula (4) or (5): ???????? HA-SP-NSAID?????(4) ???????? HA-SP-DMARD?????(5) wherein HA represents a hyaluronic acid chain; SP represents a spacer residue; NSAID represents a non-steroidal anti-inflammatory drug residue, DMARD represents a disease-modifying anti-rheumatic drug residue, and - represents the covalent bond, wherein the spacer binds to a carboxyl group of the hyaluronic acid via an amide bond and the anti-inflammatory drug selected from non-steroidal anti-inflammatory drugs and disease-modifying anti-rheumatic drugs binds to the spacer via an ester bond, an amide bond or a thioester bond.

Method for preparing 4-acetylaminophenylacetic acid

The invention discloses a method for preparing 4-acetylaminophenylacetic acid. The method includes the steps that p-nitrophenylacetic acid, N,N-dimethylacetamide and ammonium chloride are evenly mixed, heating reflux, cooling and crystallizing are conducted, and crystals are obtained to obtain 4-acetylaminophenylacetic acid. The production cost is low, the yield is high, product purity is good, operation is easy, the production period is short, and the method is suitable for industrial mass production.

ROR-GAMMA MODULATORS AND USES THEREOF

The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation. The invention further relates to pharmaceutical compositions containing the compounds and their use in the treatment of diseases or disorders mediated by RORγ.